可溶性fms样酪氨酸激酶1与胎盘生长因子比值用于预测子痫前期的研究进展

雷银; 沙梦晗; 尹恒; 陈湘漪; 赵云

doi:10.14188/j.1671-8852.2024.0956

您当前的位置：

首页 >

文章列表页 >

可溶性fms样酪氨酸激酶1与胎盘生长因子比值用于预测子痫前期的研究进展

综述 | 更新时间：2026-11-05

- 可溶性fms样酪氨酸激酶1与胎盘生长因子比值用于预测子痫前期的研究进展
- Research progress on the ratio of soluble fms like tyrosine kinase 1 to placental growth factor for predicting preeclampsia
- 武汉大学学报（医学版） 2025年46卷第9期页码：1203-1210
- 作者机构：
  
  1.武汉科技大学医学部医学院湖北武汉 430065
  2.湖北省妇幼保健院产科湖北武汉 430070
- 作者简介：
  
  雷银，女，1998—，医学硕士生，主要从事产科研究，E⁃mail:2949098972@qq.com
  尹恒，女，1978—，主任医师，主要从事产科研究，E⁃mail:yinheng@hbfy.com
- 基金信息：
  
  湖北省卫生健康委科研项目(WJ2023M109);湖北省妇幼保健院一般面上项目(2023SFYM003)
- DOI：10.14188/j.1671-8852.2024.0956
  中图分类号： R714.25
- 收稿：2024-12-10，
  
  纸质出版：2025-09-26
- 稿件说明：
移动端阅览
雷银,沙梦晗,尹恒等.可溶性fms样酪氨酸激酶1与胎盘生长因子比值用于预测子痫前期的研究进展[J].武汉大学学报（医学版）,2025,46(09):1203-1210.

LEI Yin,SHA Menghan,YIN Heng,et al.Research progress on the ratio of soluble fms like tyrosine kinase 1 to placental growth factor for predicting preeclampsia[J].Medical Journal of Wuhan University,2025,46(09):1203-1210.
雷银,沙梦晗,尹恒等.可溶性fms样酪氨酸激酶1与胎盘生长因子比值用于预测子痫前期的研究进展[J].武汉大学学报（医学版）,2025,46(09):1203-1210. DOI： 10.14188/j.1671-8852.2024.0956.

LEI Yin,SHA Menghan,YIN Heng,et al.Research progress on the ratio of soluble fms like tyrosine kinase 1 to placental growth factor for predicting preeclampsia[J].Medical Journal of Wuhan University,2025,46(09):1203-1210. DOI： 10.14188/j.1671-8852.2024.0956.

摘要

子痫前期（PE）是妊娠并发症之一，涉及母体多系统，与母儿的发病率密切相关。目前PE发病机制仍不明确，治疗手段有限，因此，预测PE以便及时采取相应防治措施成为关注的重点。尽管诸多文献已对可溶性fms样酪氨酸激酶1（sFlt⁃1）与胎盘生长因子（PLGF）预测PE进行研究和总结，但目前此比值预测和排除PE的具体标准尚未形成共识。通过查阅、梳理相关文献，本文系统介绍了PE与sFlt⁃1、PLGF及其比值相关的作用机制，总结了不同妊娠时期sFlt⁃1/PLGF预测PE发生、进展及结局的研究成果，以期为PE的预测及风险评估提供一定的参考价值和证据支持。

Abstract

Preeclampsia (PE) is one of the complications of pregnancy

which induces multisystemic maternal dysfunction and is strongly associated with adverse maternal and perinatal outcomes. At present

the pathogenesis of PE is still unclear and the treatment methods are limited. Therefore

predicting PE in order to take corresponding prevention and treatment measures in a timely manner has become a focus of attention for doctors. Although many literature have studied and summarized the relationship between soluble fms like tyrosine kinase 1 (sFlt⁃1) and placental growth factor (PLGF) in predicting PE

there is currently no consensus on the specific criteria for predicting and excluding PE using this ratio. By reviewing and organizing relevant literature

this review systematically introduces the mechanisms linking PE to sFlt⁃1

PLGF

and their ratios. It summarizes the research results on predicting the occurrence

progression

and outcome of PE with sFlt⁃1/PLGF at different stages of pregnancy

in order to provide certain reference value and evidence support for the prediction and risk assessment of PE.

关键词

Keywords

references

IVES C W , SINKEY R , RAJAPREYAR I , et al . Preeclampsia⁃pathophysiology and clinical presentations: JACC state⁃of⁃the⁃art review [J ] . J Am Coll Cardiol , 2020 , 76 ( 14 ): 1690 ⁃ 1702 .

DIMITRIADIS E , ROLNIK D L , ZHOU W , et al . Pre⁃eclampsia [J ] . Nat Rev Dis Primers , 2023 , 9 ( 1 ): 8 .

SAY L , CHOU D , GEMMILL A , et al . Global causes of maternal death: A WHO systematic analysis [J ] . Lancet Glob Health , 2014 , 2 ( 6 ): e323 ⁃ 33 .

PITTARA T , VYRIDES A , LAMNISOS D , et al . Pre⁃eclampsia and long⁃term health outcomes for mother and infant: An umbrella review [J ] . BJOG , 2021 , 128 ( 9 ): 1421 ⁃ 1430 .

POON L C , SHENNAN A , HYETT J A , et al . The international federation of gynecology and obstetrics (FIGO) initiative on pre⁃eclampsia: A pragmatic guide for first⁃trimester screening and prevention [J ] . Int J Gynaecol Obstet , 2019 , 145 ( Suppl 1 ): 1 ⁃ 33 .

ROLNIK D L , NICOLAIDES K H , POON L C . Prevention of preeclampsia with aspirin [J ] . Am J Obstet Gynecol , 2022 , 226 ( 2S ): S1108 ⁃S1119.

UNGER T , BORGHI C , CHARCHAR F , et al . 2020 international society of hypertension global hypertension practice guidelines [J ] . Hypertension , 2020 , 75 ( 6 ): 1334 ⁃ 1357 .

REDMAN C W G , STAFF A C , ROBERTS J M . Syncytiotrophoblast stress in preeclampsia: The convergence point for multiple pathways [J ] . Am J Obstet Gynecol , 2022 , 226 ( 2S ): S907 ⁃S927.

STAFF A C . The two⁃stage placental model of preeclampsia: An update [J ] . J Reprod Immunol , 2019 , 134 / 135 : 1 ⁃ 10 .

REDMAN C W , SARGENT I L , STAFF A C . IFPA Senior Award Lecture: Making sense of pre⁃eclampsia–Two placental causes of preeclampsia? [J ] . Placenta , 2014 , 35 : S20 ⁃S25.

HU X Q , ZHANG L B . Mitochondrial dysfunction in the pathogenesis of preeclampsia [J ] . Curr Hypertens Rep , 2022 , 24 ( 6 ): 157 ⁃ 172 .

POWE C E , LEVINE R J , ANANTH KARUMANCHI S . Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease [J ] . Circulation , 2011 , 123 ( 24 ): 2856 ⁃ 2869 .

PHIPPS E A , THADHANI R , BENZING T , et al . Pre⁃eclampsia: Pathogenesis, novel diagnostics and therapies [J ] . Nat Rev Nephrol , 2019 , 15 ( 5 ): 275 ⁃ 289 .

RANA S , LEMOINE E , GRANGER J P , et al . Preeclampsia: Pathophysiology, challenges, and perspectives [J ] . Circ Res , 2019 , 124 ( 7 ): 1094 ⁃ 1112 .

KALOUSOVÁ M , MURAVSKÁ A , ZIMA T . Pregnancy⁃associated plasma protein A (PAPP⁃A) and preeclampsia [J ] . Adv Clin Chem , 2014 , 63 : 169 ⁃ 209 .

GATHIRAM P , MOODLEY J . Pre⁃eclampsia: Its pathogenesis and pathophysiolgy [J ] . Cardiovasc J Afr , 2016 , 27 ( 2 ): 71 ⁃ 78 .

CRESWELL L , O'GORMAN N , PALMER K R , et al . Perspectives on the use of placental growth factor (PlGF) in the prediction and diagnosis of pre⁃eclampsia: Recent insights and future steps [J ] . Int J Womens Health , 2023 , 15 : 255 ⁃ 271 .

RYBAK⁃KRZYSZKOWSKA M , STANICZEK J , KONDRACKA A , et al . From biomarkers to the molecular mechanism of preeclampsia–a comprehensive literature review [J ] . Int J Mol Sci , 2023 , 24 ( 17 ): 13252 .

CHAU K , HENNESSY A , MAKRIS A . Placental growth factor and pre⁃eclampsia [J ] . J Hum Hypertens , 2017 , 31 ( 12 ): 782 ⁃ 786 .

MUTTER W P , ANANTH KARUMANCHI S . Molecular mechanisms of preeclampsia [J ] . Microvasc Res , 2008 , 75 ( 1 ): 1 ⁃ 8 .

MALAMITSI⁃PUCHNER A , BOUTSIKOU T , ECONOMOU E , et al . Vascular endothelial growth factor and placenta growth factor in intrauterine growth⁃restricted fetuses and neonates [J ] . Mediators Inflamm , 2005 , 2005( 5 ): 293 ⁃ 297 .

HERRAIZ I , LLURBA E , VERLOHREN S , et al . Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt⁃1/PlGF ratio in singleton pregnancies [J ] . Fetal Diagn Ther , 2018 , 43 ( 2 ): 81 ⁃ 89 .

GACCIOLI F , AYE I L M H , SOVIO U , et al . Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers [J ] . Am J Obstet Gynecol , 2018 , 218 ( 2S ): S725 ⁃S737.

WEBSTER K , FISHBURN S , MARESH M , et al . Diagnosis and management of hypertension in pregnancy: Summary of updated NICE guidance [J ] . BMJ , 2019 , 366 : 15119 .

BROWN M A , MAGEE L A , KENNY L C , et al . The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice [J ] . Pregnancy Hypertens , 2018 , 13 : 291 ⁃ 310 .

FIGO Working Group on Good Clinical Practice in Maternal⁃Fetal Medicine . Good clinical practice advice: First trimester screening and prevention of pre⁃eclampsia in singleton pregnancy [J ] . Int J Gynaecol Obstet , 2019 , 144 ( 3 ): 325 ⁃ 329 .

彭威 , 漆洪波 . ACOG“妊娠期慢性高血压指南(2019)”解读 [J ] . 中国实用妇科与产科杂志 , 2019 , 35 ( 9 ): 1014 ⁃ 1018 .

PENG W , QI H B . Interpretation of ACOG "Guidelines for Chronic Hypertension in Pregnancy (2019) " [J ] . Chin J Pract Gynecol Obstet , 2019 , 35 ( 9 ): 1014 ⁃ 1018 .

MAGEE L A , BROWN M A , HALL D R , et al . The 2021 International Society for the Study of Hypertension in pregnancy classification, diagnosis & management recommendations for international practice [J ] . Pregnancy Hypertens , 2022 , 27 : 148 ⁃ 169 .

ZEISLER H , LLURBA E , CHANTRAINE F , et al . Soluble fms⁃like tyrosine kinase⁃1⁃to⁃placental growth factor ratio and time to delivery in women with suspected preeclampsia [J ] . Obstet Gynecol , 2016 , 128 ( 2 ): 261 ⁃ 269 .

ZEISLER H , LLURBA E , CHANTRAINE F , et al . Predictive value of the sFlt⁃1: Plgf ratio in women with suspected preeclampsia [J ] . N Engl J Med , 2016 , 374 ( 1 ): 13 ⁃ 22 .

STEPAN H , HERRAIZ I , SCHLEMBACH D , et al . Implementation of the sFlt⁃1/PlGF ratio for prediction and diagnosis of pre⁃eclampsia in singleton pregnancy: Implications for clinical practice [J ] . Ultrasound Obstet Gynecol , 2015 , 45 ( 3 ): 241 ⁃ 246 .

VERLOHREN S , HERRAIZ I , LAPAIRE O , et al . The sFlt⁃1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients [J ] . Am J Obstet Gynecol , 2012 , 206 ( 1 ): 58 .e 1 ⁃ 58 .e8.

ROBERTS J M , RAJAKUMAR A . Preeclampsia and soluble fms⁃like tyrosine kinase 1 [J ] . J Clin Endocrinol Metab , 2009 , 94 ( 7 ): 2252 ⁃ 2254 .

BIAN X M , BISWAS A , HUANG X H , et al . Short⁃term prediction of adverse outcomes using the sFlt⁃1 (soluble fms⁃like tyrosine kinase 1)/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia [J ] . Hypertension , 2019 , 74 ( 1 ): 164 ⁃ 172 .

ZEISLER H , LLURBA E , CHANTRAINE F J , et al . Soluble fms⁃like tyrosine kinase⁃1 to placental growth factor ratio: Ruling out pre⁃eclampsia for up to 4 weeks and value of retesting [J ] . Ultrasound Obstet Gynecol , 2019 , 53 ( 3 ): 367 ⁃ 375 .

VERLOHREN S , HERRAIZ I , LAPAIRE O , et al . New gestational phase⁃specific cutoff values for the use of the soluble fms⁃like tyrosine kinase⁃1/placental growth factor ratio as a diagnostic test for preeclampsia [J ] . Hypertension , 2014 , 63 ( 2 ): 346 ⁃ 352 .

FOREST J C , THÉRIAULT S , MASSÉ J , et al . Soluble Fms⁃like tyrosine kinase⁃1 to placental growth factor ratio in mid⁃pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women [J ] . Clin Chem Lab Med , 2014 , 52 ( 8 ): 1169 ⁃ 1178 .

SOUNDARARAJAN R , SURESH S C , MUELLER A , et al . Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: Robust study [J ] . Pregnancy Hypertens , 2021 , 23 : 97 ⁃ 103 .

LEAÑOS⁃MIRANDA A , GRACIELA NOLASCO⁃LEAÑOS A , ISMAEL CARRILLO⁃JUÁREZ R , et al . Usefulness of the sFlt⁃1/PlGF (soluble fms⁃like tyrosine kinase⁃1/placental growth factor) ratio in diagnosis or misdiagnosis in women with clinical diagnosis of preeclampsia [J ] . Hypertension , 2020 , 76 ( 3 ): 892 ⁃ 900 .

RANA S , POWE C E , SALAHUDDIN S , et al . Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia [J ] . Circulation , 2012 , 125 ( 7 ): 911 ⁃ 919 .

BALTAJIAN K , BAJRACHARYA S , SALAHUDDIN S , et al . Sequential plasma angiogenic factors levels in women with suspected preeclampsia [J ] . Am J Obstet Gynecol , 2016 , 215 ( 1 ): 89 .e1⁃89.89.e10.

PEGUERO A , FERNANDEZ⁃BLANCO L , MAZARICO E , et al . Added prognostic value of longitudinal changes of angiogenic factors in early⁃onset severe pre⁃eclampsia: A prospective cohort study [J ] . BJOG , 2021 , 128 ( 2 ): 158 ⁃ 165 .

PEGUERO A , HERRAIZ I , PERALES A , et al . Placental growth factor testing in the management of late preterm preeclampsia without severe features: A multicenter, randomized, controlled trial [J ] . Am J Obstet Gynecol , 2021 , 225 ( 3 ): 308 .e 1 ⁃ 308 .e14.

DRÖGE L A , PERSCHEL F H , STÜTZ N , et al . Prediction of preeclampsia⁃related adverse outcomes with the sFlt⁃1 (soluble fms⁃like tyrosine kinase 1)/PlGF (placental growth factor)⁃ratio in the clinical routine: A real⁃world study [J ] . Hypertension , 2021 , 77 ( 2 ): 461 ⁃ 471 .

STEPAN H , GALINDO A , HUND M , et al . Clinical utility of sFlt⁃1 and PlGF in screening, prediction, diagnosis and monitoring of pre⁃eclampsia and fetal growth restriction [J ] . Ultrasound Obstet Gynecol , 2023 , 61 ( 2 ): 168 ⁃ 180 .

GÓMEZ⁃ARRIAGA P I , HERRAIZ I , LÓPEZ⁃JIMÉNEZ E A , et al . Uterine artery Doppler and sFlt⁃1/PlGF ratio: Usefulness in diagnosis of pre⁃eclampsia [J ] . Ultrasound Obstet Gynecol , 2013 , 41 ( 5 ): 530 ⁃ 537 .

HERRAIZ I , SIMÓN E , GÓMEZ⁃ARRIAGA P I , et al . Clinical implementation of the sFlt⁃1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study [J ] . Pregnancy Hypertens , 2018 , 13 : 279 ⁃ 285 .

GACCIOLI F , SOVIO U , COOK E , et al . Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: A prospective cohort study [J ] . Lancet Child Adolesc Health , 2018 , 2 ( 8 ): 569 ⁃ 581 .

ESPINOZA J , ROMERO R , NIEN J K , et al . Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor [J ] . Am J Obstet Gynecol , 2007 , 196 ( 4 ): 326 .e1⁃326.13.

SALAHUDDIN S , WENGER J B , ZHANG D S , et al . KRYPTOR⁃automated angiogenic factor assays and risk of preeclampsia⁃related adverse outcomes [J ] . Hypertens Pregnancy , 2016 , 35 ( 3 ): 330 ⁃ 345 .

HEIMBERGER S , MUELLER A , RATNAPARKHI R , et al . Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension [J ] . Pregnancy Hypertens , 2020 , 20 : 124 ⁃ 130 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

子痫前期患者胎盘组织P57kip2 mRNA水平及与血清sFlt‑1、PLGF的关系

尿白细胞介素⁃37预测脓毒症患者28天死亡率的价值

佛手柑内酯可能通过靶向HSD11B2抑制子痫前期进展

常春藤皂苷元对压力超负荷诱导的小鼠心肌肥厚及纤维化的影响

静脉血栓栓塞症预防健康教育的研究进展